Retour à la liste des essais cliniquesChildhood and adolescent cancers

GSK213406

A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

Ouvert à Paris depuis le : 01/04/2021
Public cible : Child
Phase : Phase I

Description de l'essai

This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the pediatric population. This study will be conducted to determine the recommended Phase 2 dose (RP2D) and evaluate the pharmacokinetics (PK), safety, and efficacy of niraparib in combination with dostarlimab in pediatric participants with recurrent or refractory solid tumors.

Url of the trial

Investigateur principal

FRANCOIS DOZ

Professeur - Médecin

Contacter